SEQUENTIAL GN-RH SUPERAGONIST AND MEDROXYPROGESTERONE ACETATE TREATMENT OF UTERINE LEIOMYOMATA

被引：22

作者：

BENAGIANO, G

MORINI, A

ALEANDRI, V

PICCINNO, F

PRIMIERO, FM

ABBONDANTE, G

ELKINDHIRSCH, K

机构：

[1] UNIV ROME LA SAPIENZA,INST OBSTET & GYNECOL 1,I-00185 ROME,ITALY

[2] BAYLOR UNIV,DEPT OBSTET & GYNECOL,HOUSTON,TX 77030

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS | 1990年 / 33卷 / 04期

关键词：

Buserelin; Gn-RH analogs; Medroxyprogesterone acetate; Pharmacologic treatment of fibroids;

D O I：

10.1016/0020-7292(90)90520-U

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

A group of 48 women with symptomatic leiomyomata were treated during 6 months with the short-acting Gn-RH superagonist analog buserelin. The first (group C) was followed up for an additional six months of no medication. The second (group M) was treated for 6 additional months with medroxyprogesterone acetate (MPA) at doses decreasing from 200 to 25 mg/day. Buserelin therapy significantly decreased uterine size (P < 0.001) in all patients, the average final volume being 48.5% of the original (from 262 ± 147 ml to 127 ± 85.4 ml). In group C there was a significant (P < 0.001) re-growth during the post-treatment observation period (from 120 ± 81.0 ml to 198 ± 77.2 ml); a significant (P < 0.01) re-growth was also observed in group M during MPA medication (from 132 ± 77.2 ml to 170 ± 96.0 ml). The agonist had also a marked effect on fibroids: on average they decreased from 75.1 ± 74.3 ml to 24.7 ± 23.3 ml (P < 0.025). In group C during the post-buserelin period of observation without treatment, there was a significant re-growth from 23.7 ± 21.6 ml to 47.7 ± 27.5 ml (P < 0.001), whereas in group M treatment with MPA prevented any significant re-growth (from 25.6 ± 24.8 to 30.6 ± 32.9 ml; P > 0.3). © 1990.

引用

页码：333 / 343

页数：11

共 26 条

[1]

Anderson, Peck, Clark, Estrogen-induced uterine responses and growth: Relationship to receptors-estrogen binding by uterine nuclei, Endocrinology, 96, (1975)

[2]

Andreyko, Blumenfeld, Marshall, Monroe, Hricak, Jaffe, Use of an agonistic analog of gonadotropin-releasing hormone (nafarelin) to treat leiomyomas: assessment by magnetic resonance imaging, Am J Obstet Gynecol, 158, (1988)

[3]

Baird, West, Medical management of fibroids, Br Med J, 296, (1988)

[4]

Baird, Bramley, Hawkins, Lumsden, West, Effect of treatment with LHRH analogue zoladex on binding of oestradiol, progesterone and epidermal growth factor to uterine fibromyomata, Hormone Res, 32, (1989)

[5]

Buttram, Reiter, Uterine leiomyomata: etiology, symptomatology, and management., Fertil Steril, 36, (1981)

[6]

Corbin, Beattie, Tracy, Jones, Foell, Yardley, Rees, The anti-reproductive pharmacology of LHRH and agonist analogues, Int J Fertil, 23, (1978)

[7]

Crona, Enk, Samsioe, Silfverstalpe, Skryten, High-dose depot-medroxyprogesterone acetate (DMPA) — effects on lipid and lipoprotein metabolism, European Journal of Obstetrics & Gynecology and Reproductive Biology, 16, (1983)

[8]

Fahraeus, Sydsjo, Wallentin, Lipoprotein changes during treatment of pelvic endometriosis with medroxyprogesterone acetate., Fertil Steril, 45, (1986)

[9]

Filicori, Hall, Loughlin, Rivier, Vale, Crowley, A conservative approach to the management of uterine leiomyoma: pituitary desensitization by a luteinizing hormone-releasing hormone analogue, Am J Obstet Gynecol, 147, (1983)

[10]

Friedman, Barbieri, Doubilet, A randomized, double-blind trial of a gonadotropin releasing-hormone agonist (leuprolide) with or without medroxyprosterone acetate in the treatment of leiomyomata uteri, Fertil Steril, 49, (1988)

← 1 2 3 →